DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Bulletin > Acta Medica Nagasakiensia > Volume 39, No. 1-3 >

Donor Pretreatment With PAF Antagonist TCV - 309 Enhances Lung Preservation


File Description SizeFormat
acta39_01_24_t.pdf994.28 kBAdobe PDFView/Open

Title: Donor Pretreatment With PAF Antagonist TCV - 309 Enhances Lung Preservation
Authors: Ide, Seiichiro
Issue Date: 25-Oct-1994
Citation: Acta medica Nagasakiensia. 1994, 39(1-3), p.130-137
Abstract: background and purpose Considerable efforts have been made to understand the physiological roles of PAF in organ transplantation and heart-lung and lung transplantation using several different PAF receptor antagonists. Experimentally pulmonary dysfunctions manifested as low oxygen tension, high pulmonary vascular resistance, decreased pulmonary compliance and lung edema following transplantation are similar to the pathophysiological manifestations of PAF. methods In the present study determination of the optimum time to administer PAF antagonist was elucidated for beneficial effects and also the function of the graft was assessed. Canine single lung allo transplantation was performed after 24-hour preservation of a donor lung. The PAF antagonist TCV-309 was added to the Euro- Collins solution in all groups, and in Group 1 which served as control group, no other pharmacological intervantion was done. In Group 2 TCV-309 was adnministered to the recipient prior to reperfusion. In Group 3 TCV-309 was administered to the donor prior to organ harvesting and administered to the recipient prior to reperfusion. results Optimum posttransplant graft function and superior recipient's survival was obtained in Group 3. One hour after reperfusion, the Pa02 in Group 3 was significantly higher than those in Group 1 and 2: 327±181 mm Hg versus 152±95.2 mm Hg and 151±143 mm Hg; (p <0.05). In every group posttransplant pulmonary function deteriorated until the 4th postoperative day though in Group 2 and 3 pulmonary venous oxygen tension, extravascular thermal volume and myeloperoxidase activity in the lung tissue was restored by the 14th postoperative day. conclusions It is a clue in achieving a great success of lung transplantation to administer the PAF antagonist TCV-309 to the donor, and TCV-309 shows considerable promise in improving the function of the 24 hour hypothermic preserved canine lung allografts after reperfusion.
URI: http://hdl.handle.net/10069/15985
ISSN: 00016055
Type: Departmental Bulletin Paper
Text Version: publisher
Appears in Collections:Volume 39, No. 1-3

Citable URI : http://hdl.handle.net/10069/15985

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace